COVID-19 백신 투여 이후 발생한 심한 사지 자반증이 절단을 요하는 당뇨발에 미치는 영향: 증례 보고
Effect of Severe Limb Purpura Following the Administration of COVID-19 Vaccination on a Diabetic Foot Requiring Amputation: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The current SARS-CoV-2 coronavirus disease 2019 (COVID-19) pandemic has been a particular challenge for diabetes patients. Since these patients are at a higher risk of COVID-19, they have been prioritized for vaccination. In this report, we describe the case of a patient scheduled for diabetic foot amputation who received the first dose of ChAdOx1 nCov-19 vaccine and subsequently developed severe purpura in his genitalia and both of his hands and feet, accompanied by acute renal failure. The operation had to be postponed as severe limb purpura appeared just before the operation. With adequate management for acute renal failure and topical steroid applica- tion for the severe purpura lesions, a successful outcome could be obtained after the delayed first ray amputation. We recommend that COVID-19 vaccination should be carefully administered in patients with a diabetic foot requiring amputation.
Abstract
The current SARS-CoV-2 coronavirus disease 2019 (COVID-19) pandemic has been a particular challenge for diabetes patients. Since these patients are at a higher risk of COVID-19, they have been prioritized for vaccination. In this report, we describe the case of a patient scheduled for diabetic foot amputation who received the first dose of ChAdOx1 nCov-19 vaccine and subsequently developed severe purpura in his genitalia and both of his hands and feet, accompanied by acute renal failure. The operation had to be postponed as severe limb purpura appeared just before the operation. With adequate management for acute renal failure and topical steroid applica- tion for the severe purpura lesions, a successful outcome could be obtained after the delayed first ray amputation. We recommend that COVID-19 vaccination should be carefully administered in patients with a diabetic foot requiring amputation.
참고문헌 (15)
- Pormohammad A, "Efficacy and safety of COVID-19 vaccines : a systematic review and meta-analysis of randomized clinical trials", Vaccines(Basel), 9, pp.467~ (2021)[DOI]
- Forni G, "COVID-19 vaccines : where we stand and challenges ahead", Cell Death Differ, 28, pp.626~639 (2021)[DOI]
- World Health Organization, "COVID-19 vaccine tracker and landscape", World Health Organization, ~ (2021)
- Cines DB, "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia", N Engl J Med, 384, pp.2254~2256 (2021)[DOI]
- Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)[DOI]
- Schultz NH, "Thrombosis and thrombocytopenia after ChAdOx1nCoV-19 vaccination", N Engl J Med, 384, pp.2124~2130 (2021)
- Pottegård A, "Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway : population based cohort study", BMJ, 373, pp.n1114~ (2021)[DOI]
- Scully M, "Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination", N Engl J Med, 384, pp.2202~2211 (2021)[DOI]
- Simpson CR, "First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland", Nat Med, 27, pp.1290~1297 (2021)[DOI]
- Kharkar V, "Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance", Clin Exp Dermatol, 46, pp.1596~1597 (2021)[DOI]
- Cohen SR, "Leukocytoclastic vasculitis flare following the COVID-19 vaccine", Int J Dermatol, 60, pp.1032~1033 (2021)[DOI]
- Bostan E, "New-onset leukocytoclastic vasculitis after COVID-19 vaccine", Int J Dermatol, 60, pp.1305~1306 (2021)[DOI]
- Watanabe T, "Vasculitis following influenza vaccination : a review of the literature", Curr Rheumatol Rev, 13, pp.188~196 (2017)[DOI]
- Bonetto C, "Vasculitis as an adverse event following immunization-systematic literature review", Vaccine, 34, pp.6641~6651 (2016)[DOI]
- Guimarães LE, "Vaccines, adjuvants and autoimmunity", Pharmacol Res, 100, pp.190~209 (2015)[DOI]